Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Gesine B. Jaissle & Peter Szurman & Nicolas Feltgen & Bernhard Spitzer & Amelie Pielen & Matus Rehak & Georg Spital & Heinrich Heimann & Carsten H. Me
- چاپ و سال / کشور: 2010
Description
Background To identify predictive factors for improvement of visual acuity and central retinal thickness by intravitreal bevacizumab for the treatment of macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods Two hundred and five eyes from 204 patients with ME secondary to BRVO were retrospectively included at six sites. All eyes received intravitreal bevacizumab therapy (1.25mg/0.05 ml). Themean follow-up was 36.8±12.7weeks (range, 18 to 54 weeks). Measurement of ETDRS bestcorrected visual acuity (BCVA, in all eyes) and optical coherence tomography (OCT, in 87% of eyes) were performed at baseline and at follow-up examinations every 12 weeks. Using fluorescein angiography, the perfusion status of themacula at baseline could be assessed in 84%of the eyes. The main outcome measures were changes in BCVA and central retinal thickness (CRT). For analysis of predictive factors, the results at 24 weeks were used. Results The median BCVA was 0.6 LogMAR at baseline and improved to 0.4 LogMAR at 24 and 48 weeks. This visual improvement was associated by a significant reduction in CRT, decreasing from a baseline of 454 ìm to 267 ìm and 248 ìm after 24 and 48 weeks respectively. Eyes with ME and intact (perfused) or interrupted (ischemic) foveal capillary ring showed a 2-line increase of median BCVA [45 eyes (22%) and 128 eyes (62%) respectively]. However, the final median BCVA was significantly worse in eyes with ischemic ME (0.6 versus
Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192 DOI 10.1007/s00417-010-1470-2 Received: 1 February 2010 / Revised: 15 July 2010 / Accepted: 17 July 2010 / Published online: 18 August 2010
